The tirzepatide EPAR explained for UK patients

You're reading the EPAR, here's what it actually is

Picture this: you've found a dense PDF on the EMA's website, several hundred pages long, written in clinical shorthand. That document is the European Public Assessment Report for tirzepatide. The EMA publishes EPARs for medicines it has assessed for the EU market, and they are genuinely thorough. For tirzepatide, the EPAR covers the full SURMOUNT trial programme, Eli Lilly's manufacturing dossier, the pharmacological profile (tirzepatide acts simultaneously on GIP and GLP-1 receptors, making it the only dual-agonist weight-loss medicine available in the UK), the benefit-risk balance, and the conditions attached to EU approval.

It is a useful scientific reference. For a UK patient trying to understand what the medicine does and what the trials found, the clinical sections are largely applicable, because the underlying trial data is the same data the MHRA reviewed. Thousands of adults across the SURMOUNT-1 trial alone (2,539 participants over 72 weeks) provided the efficacy and safety evidence that both regulators examined. You can read a plain-English summary of that evidence on the tirzepatide overview page if the EPAR feels like too much to wade through at once.

The EPAR is published on the EMA's website and is updated when new data or safety information emerges. Sections on post-marketing obligations and risk management are especially worth noting if you want to understand what ongoing monitoring the manufacturer must do. According to the BNF's tirzepatide entry, the medicine carries a Black Triangle (▼) status in the UK, meaning the MHRA requires enhanced vigilance and reporting.

Why the MHRA's decision is the one that matters for Mounjaro in Britain

After Brexit, the UK's Medicines and Healthcare products Regulatory Agency became the independent licensing authority for medicines used in Great Britain. It no longer automatically follows EMA decisions. When Eli Lilly sought approval for tirzepatide for weight management in the UK, the MHRA conducted its own review. The resulting Mounjaro UK licence sets the indications, approved doses (2.5 mg through to 15 mg), and the SmPC that governs how prescribers use it here.

That independence matters practically. There are cases where the EMA and MHRA reach the same conclusion at slightly different times, or where the approved indications carry minor differences in wording. For tirzepatide, both authorities approved it for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition, as an adjunct to a reduced-calorie diet and physical activity. The SmPC on the electronic Medicines Compendium (eMC) is the definitive UK reference for licensed indications, contraindications and storage; the EPAR is useful context but it does not override the UK SmPC.

If you want to understand how Mounjaro compares to semaglutide as licensed options in the UK, the Mounjaro or tirzepatide guide covers that clearly. And if cost is on your mind, the Mounjaro price context page explains what private treatment typically involves.

What the EPAR's safety data tells you

The safety sections of the EPAR are the parts most relevant to a patient reading it. They reflect the adverse-event data from the SURMOUNT trials and, importantly, any signals identified during the EU regulatory review. The dominant side-effect profile is gastrointestinal: nausea, vomiting, diarrhoea, constipation and reflux featured most often in the trials, particularly after starting treatment or following a dose step, and our tirzepatide L page covers how the later maintenance doses fit into that escalation journey. These effects were generally mild to moderate and tended to ease as participants' systems adjusted.

Pancreatitis is flagged in both the EPAR and the UK SmPC as a known, infrequent but potentially serious risk. The MHRA reinforced this with a Drug Safety Update in January 2026 for GLP-1 medicines as a class, noting that severe, persistent abdominal pain, especially pain that radiates to the back, warrants urgent medical attention. The NHS's patient information for tirzepatide summarises the side-effect profile in plain English and is the most accessible starting point for most readers.

The EPAR also documents the MHRA's equivalent category of enhanced pharmacovigilance, applied via the Black Triangle scheme. Patients and healthcare professionals in the UK can report any suspected side effects through the MHRA Yellow Card scheme. It is worth knowing that reports from real-world use genuinely inform regulatory decisions; the EPAR is updated when post-marketing data changes the risk picture. If you have questions about specific side effects, our clinical team can help, details are on the prescriber profile page.

Reading the EPAR alongside UK eligibility guidance

One point that trips people up: the EPAR describes the licensed indication for tirzepatide, which covers a fairly broad adult weight-management population. NICE's appraisal (TA1026) then layers additional eligibility requirements on top for NHS prescribing in England, including a BMI threshold of 35 or above and the presence of at least one qualifying comorbidity for the current cohort phases, and if you are curious about how a specific supply format such as tirzepatide 30 fits within the licensed dose range, that page sets it out clearly. Those NHS eligibility rules are not in the EPAR at all; they are a domestic health technology assessment decision about cost-effectiveness and NHS prioritisation.

Private prescribing follows the licensed label rather than NICE's NHS-specific criteria, which is why patients who do not yet meet NHS thresholds may still be clinically eligible for treatment through a regulated online pharmacy. Our weight-loss treatment overview explains both routes honestly. A prescriber will assess the full picture, not just a BMI number, and patients who are earlier in their treatment journey may find it helpful to read about tirzepatide 10 as a dose step within the escalation schedule before their consultation. When you are ready, you can start a free consultation and have your answers reviewed by a named, GPhC-registered Independent Prescriber the same day.